Background: Respiratory syncytial virus (RSV) may cause fatal lower respiratory tract
| INTRODUCTION
Respiratory syncytial virus (RSV) is the most common cause of serious respiratory infection in infants and young children, leading to >100 000 hospitalizations and 300 deaths each year in the United
States.
1 Reinfection is common throughout life and generally results in mild disease in healthy young adults. However, severe RSV disease may occur in the elderly and in adults with chronic cardiopulmonary disease or compromised immune function. 2, 3 Recipients of lung transplant or hematopoietic stem cell transplant (HSCT) are at particularly high risk of severe RSV infection. 4 Mortality rates in HSCT patients who develop RSV lower respiratory tract disease (LRTI) range from
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20% to 40% and may be as high as 100% in those with respiratory failure. [5] [6] [7] [8] [9] Optimal therapy for immunocompromised patients with RSV infection has not been defined and data on treatment are limited. Inhaled ribavirin (Virazole ® ) is US Food and Drug Administration (FDA) approved only for use in RSV-infected hospitalized infants and young children. This drug has been used off-label in oral, intravenous, and inhaled formulations in immunocompromised patients with RSV, despite questionable efficacy. 10, 11 A second option for treatment of RSV infection is immunoglobulin, generally combined with ribavirin. 8, 12, 13 Presently, two immunoglobulin products are available, including the monoclonal antibody palivizumab (Synagis ® , MedImmune, Gaithersburg, MD, USA), approved for prophylaxis in high-risk infants, and pooled human intravenous immunoglobulin (IVIG). Because palivizumab is dosed based on weight and is costly, IVIG is generally used in adults when an immunoglobulin product is used. 14 
| METHODS

| Patients
| Study product
RI
| Product infusion
Patients were treated on day 1 with RI-001 1500 mg/kg, followed 2 days later with 750 mg/kg on day 3. RI-001 drug concentration was 100 mg/mL. Infusion rate was gradually increased from 0.3 mL/kg/ hour to 2.0 mL/kg/hour (maximum 150 mL/hour) at 15 minute intervals over a 2-hour period. If an infusion reaction occurred, sites were instructed to slow or stop the infusion until symptoms resolved and to re-start the infusion at a lower rate, slowly increasing the rate as tolerated by the patient. Pre-medication per institutional guidelines was permitted.
| Microneutralization antibody assay
Serum neutralizing antibody titers were performed by use of an established microneutralization method for RSV A strain. 15 In brief, serum dilutions were incubated with 75 pfu of RSV A2 strain (group A virus) for 30 minutes at room temperature, followed by the addition of
1.5×10
4 HEp-2 cells in 96-well culture plates. After 3 days, the quantity of RSV antigen was determined by enzyme immunosorbant assay using monoclonoal antibody to the RSV F protein. The neutralization titer was defined as the serum dilution that results in a 50% reduction in color development.
| Statistical analysis
Means between groups were compared by Student's t-test; proportions were compared by Fisher's exact test.
| RESULTS
| Population
A total of 15 patients ranging in age from 2 months to 71 years of age received compassionate use RI-001 (Table 1) . Sixty percent were male and 53% were <18 years of age. Patients with a variety of underlying medical conditions received RI-001 including the following: recipients of bone marrow transplants or HSCT (9), hematologic malignancy (3), severe combined immunodeficiency (1), liver transplant (1), and interstitial lung disease (1). Four HSCT recipients were pre-engraftment and 3 had chronic graft-versus-host disease at the time their RSV infection was identified.
| RSV illness
Diagnosis of RSV was most often made by detecting RSV in upper airway secretions by antigen detection or PCR, but RSV was also de- 
| Treatment of RSV infection
| RI-001 treatment
All patients received a minimum 2 doses of RI-001 of whom 13 (87%)
were dosed per the sponsor's instructions, receiving 1500 mg/kg of RI-001 as an IV infusion, followed 2 days later by 750 mg/kg. Two patients did not receive product according to the sponsor's instructions:
One patient received the second dose of RI-001 on day 4 and one patient received 4 doses of RI-001 at 1500 mg/kg on days 1, 3, 5, and 7.
Three patients were judged to have infusion-related adverse events.
One subject had back pain and elevated blood pressure with the first dose, but tolerated the second dose without incident. Two patients had infusion-related symptoms that resolved after slowing the infusion, and the second doses were well tolerated with pre-medication.
No serious adverse events related to study product were noted.
| Antibody measurements
Fourteen patients had pre-treatment and at least one post-infusion serum sample available for measurement of serum neutralizing antibody against RSV ( Table 2 ). The pre-infusion titers ranged from 51 to 
| Illness outcomes
Of the 15 patients treated, 7 required intensive care treatment, 6 assisted ventilation (2 non-invasive and 4 mechanical ventilation) during their RSV infection (Table 3 ). All patients who required mechanical ventilation died, and 3 of the 4 had respiratory failure before receipt of RI-001. Eleven of 15 (73%) patients had improvement of their respiratory infection and survived the hospitalization. Of these, one had refractory leukemia and was discharged to home with comfort care.
Four patients (2 children and 2 adults) died of progressive respiratory failure during the hospitalization. No apparent differences in survival were observed between patients with underlying malignant diseases (9 patients, 2 deaths) and those with non-malignant diseases (6 patients, 2 deaths). In addition, no differences in survival were observed in patients who had undergone bone marrow or HSCT vs those who had not. Survival was 0/4 (0%) for patients with respiratory failure compared to 11/11 (100%), P<.001 in those without respiratory failure.
Time from onset of respiratory symptoms and time from RSV diagnosis to initiation of RI-001 treatment were evaluated (Table 4) .
Patients who had significant underlying illness, such as congestive heart failure, that complicated interpretation of dyspnea, or had chronic relapsing RSV, were evaluated in two ways: time from onset of any respiratory symptom and time from new respiratory symptoms relating to RSV infection. Time from RSV diagnosis and from onset of new respiratory symptoms to treatment with RI-001 was significantly shorter among survivors compared to non-survivors.
| DISCUSSION
RSV remains a cause of significant morbidity and mortality in patients with immune deficiencies and, although mortality rates from RSV LRTI have dropped from 50%-100% in initial reports to 20%-40% in more recent reviews, better therapies are clearly still needed. 16 Lower mortality rates likely reflect more sensitive diagnostics, better supportive care, and earlier more aggressive treatment. Yet the benefit of specific antiviral treatment remains difficult to define. Optimal treatment of RSV infection in this population is controversial primarily owing to the lack of definitive randomized controlled trials. Small case series, heterogeneous populations, and lack of standardized treatment regimens make interpretation of the literature challenging. However, several retrospective studies and a recent pooled analysis suggest that ribavirin in any form is associated with decreased progression of upper respiratory tract infection (URTI) to LRTI (45% down to 16%) and decreased mortality (70% down to 13%). 8, 9 Although observational data suggest benefit of early treatment with ribavirin, multiple issues remain, including high cost ($29 953/day) toxicity, and administration difficulties with the inhaled preparation and of IV ribavirin. have not demonstrated clinical advantage, it is possible that immunodeficient patients might derive benefit. 20 Supporting this concept, immunosuppressed cotton rats treated with RI-002 (the second derivative of RI-001) were protected from RSV infection in the lower airways and resultant pulmonary inflammation. 21 In addition to an antiviral effect, immunoglobulins are known to have anti-inflammatory effects that may be beneficial when used in combination with antiviral agents.
22
Despite the theoretical benefit, the use of immunoglobulin products to treat RSV infection in immunosuppressed patients remains controversial, in part because standard IVIG or palivizumab was used in combination with ribavirin at the discretion of the treating physician. 9 In a review of 407 HSCT patients, treatment with aerosolized T A B L E 2 Neutralizing antibody levels with ribavirin alone.
12
The importance of achieving a specific level of RSV antibody in transplant patients is unknown. In one study of HSCT patients, serum neutralizing antibody levels were not significantly different in those who progressed from URTI to LRTI compared to non-progressors. 6 In contrast, in a study of 56 RSV-infected HSCT recipients, of whom 71% Such mutants have been produced in vitro and have been found in 5%-9% of children with RSV breakthrough episodes while receiving palivizumab prophylaxis. 25, 26 Although not a significant clinical problem in immunocompetent children, resistant viruses might be more likely to develop because of prolonged shedding and higher levels of virus in immunosuppressed children. Polyclonal RSV antibody preparations such as RI-001, which has standardized concentrations of RSV antibody and meets the FDA guidance for treatment of patients with immune deficiency, could address both these issues.
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Our experience with 15 patients who received RI-001 as compassionate use indicates the product is safe and well tolerated with minimal side effects. RI-001 produced at least a 4-fold rise in RSV neutralizing titers in all patients, and in some had 24-to 76-fold increases.
These results highlight the advantage of using RI-001 over standard IVIG in achieving high serum neutralizing titers in patients.
Caution is necessary in drawing conclusions regarding efficacy of RI-001 in the absence of a randomized study. While the mortality rate of 27% in our cohort is similar to the 22%-24% mortality rates in similar patients using ribavirin alone or with IVIG, it is important to note that 9 patients in our cohort were judged to be failing con- T A B L E 4 Timing of RI-001 treatment
